Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma.

ABSTRACT:

Abstract

Patients with relapsed/refractory multiple myeloma (RRMM) frequently develop drug resistance, leading to poor survival outcomes. Zevorcabtagene autoleucel (zevor-cel or CT053) is a fully human B-cell maturation antigen, targeting chimeric antigen receptor (CAR) T-cell therapy for patients with RRMM. The phase 1 part of LUMMICAR study 1 was a single-arm, open-label, multi-center study conducted in China, enrolling patients with RRMM who received ≥3 prior regimens. Safety, tolerability, efficacy, and pharmacokinetics were evaluated. Fourteen patients (50% male) received single infusion of zevor-cel (100 × 106 [n = 3] and 150 × 106 CAR T cells [n = 11]). As of 22 February 2025, with the median follow-up duration of 53.3 months (range, 14.8-63.5), 13 (92.9%) patients experienc

SUBMITTER: Fu C 

PROVIDER: S-EPMC12856346 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature